{
    "organizations": [],
    "uuid": "bfb449d191a21f912ea0479ace4531e5b84584f9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-roche-holding-ag-ceo-says-very-con/brief-roche-holding-ag-ceo-says-very-confident-we-can-grow-in-spite-of-the-entry-of-biosimilars-idUSFWN1S307K",
    "ord_in_thread": 0,
    "title": "BRIEF-Roche Holding AG CEO Says Very Confident We Can Grow In Spite Of The Entry Of Biosimilars",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 26 (Reuters) - Roche Holding AG:\n* CEO SAYS CONFIDENT OF ROCHEâ€™S ABILITY TO CONTINUE GROWTH BEYOND 2018 DESPITE BIOSIMILAR ENTRIES\n* CEO SAYS INCREASE IN GUIDANCE IS FOR BOTH SALES AND EPS * DRUG DIVISION CHIEF SAYS RITUXAN DECLINE IN EUROPE WAS BROADLY EXPECTED, SEES EUROPEAN EROSION TO CONTINUE IN SECOND HALF OF YEAR COUPLED WITH ARRIVAL OF FIRST HERCEPTIN COPY\n* DRUG DIVISION CHIEF SAYS STILL CONFIDENT CAN COMPENSATE FOR BIOSIMILAR EROSION OF OLDER DRUGS\n* DRUG DIVISION CHIEF SEES CONTINUED STRONG OCREVUS GROWTH * CEO SAYS WE ARE ON THE CONSTANT LOOKOUT FOR NEW TECHNOLOGIES, WE SCREEN THE MARKET FOR OPPORTUNITIES\n* CEO SAYS CONTINUES TO LOOK FOR BOLT-ON ACQUISITIONS\n* CEO SAYS TYPICALLY DOES NOT MAKE SENSE TO PURSUE LATE-STAGE TRANSACTIONS THAT END UP IN BIDDING PROCESS, CLEARLY HAS FOCUS ON EARLIER STAGE ASSETS\n* CEO SAYS HAS 15 NEW MOLECULAR ENTITITES IN LATE STAGE PORTFOLIO\n* CEO SAYS VERY CONFIDENT WE CAN GROW IN SPITE OF THE ENTRY OF BIOSIMILARS Source text for Eikon: (Reporting by John Miller)\n ",
    "published": "2018-04-26T14:30:00.000+03:00",
    "crawled": "2018-04-26T09:47:58.014+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "roche",
        "holding",
        "ag",
        "ceo",
        "say",
        "confident",
        "roche",
        "ability",
        "continue",
        "growth",
        "beyond",
        "despite",
        "biosimilar",
        "entry",
        "ceo",
        "say",
        "increase",
        "guidance",
        "sale",
        "eps",
        "drug",
        "division",
        "chief",
        "say",
        "rituxan",
        "decline",
        "europe",
        "broadly",
        "expected",
        "see",
        "european",
        "erosion",
        "continue",
        "second",
        "half",
        "year",
        "coupled",
        "arrival",
        "first",
        "herceptin",
        "copy",
        "drug",
        "division",
        "chief",
        "say",
        "still",
        "confident",
        "compensate",
        "biosimilar",
        "erosion",
        "older",
        "drug",
        "drug",
        "division",
        "chief",
        "see",
        "continued",
        "strong",
        "ocrevus",
        "growth",
        "ceo",
        "say",
        "constant",
        "lookout",
        "new",
        "technology",
        "screen",
        "market",
        "opportunity",
        "ceo",
        "say",
        "continues",
        "look",
        "acquisition",
        "ceo",
        "say",
        "typically",
        "make",
        "sense",
        "pursue",
        "transaction",
        "end",
        "bidding",
        "process",
        "clearly",
        "focus",
        "earlier",
        "stage",
        "asset",
        "ceo",
        "say",
        "new",
        "molecular",
        "entitites",
        "late",
        "stage",
        "portfolio",
        "ceo",
        "say",
        "confident",
        "grow",
        "spite",
        "entry",
        "biosimilars",
        "source",
        "text",
        "eikon",
        "reporting",
        "john",
        "miller"
    ]
}